Multivariable model for OS
| Variable . | P . | Hazard ratio . | Hazard ratio lower bound (95%) . | Hazard ratio upper bound (95%) . |
|---|---|---|---|---|
| Platelets (× 109/L) | .136 | 0.999 | 0.997 | 1.000 |
| TP53 monoallelic | .003 | 2.081 | 1.286 | 3.369 |
| TP53 multihit | <.0001 | 2.952 | 1.917 | 4.545 |
| Stem cell transplant | <.0001 | 0.344 | 0.000 | 0.505 |
| Therapy administered | ||||
| Low-intensity therapies* | .005 | 0.529 | 0.000 | 0.827 |
| HMA/venetoclax* | .010 | 0.496 | 0.000 | 0.845 |
| Induction therapy* | .236 | 0.732 | 0.437 | 1.226 |
| Variable . | P . | Hazard ratio . | Hazard ratio lower bound (95%) . | Hazard ratio upper bound (95%) . |
|---|---|---|---|---|
| Platelets (× 109/L) | .136 | 0.999 | 0.997 | 1.000 |
| TP53 monoallelic | .003 | 2.081 | 1.286 | 3.369 |
| TP53 multihit | <.0001 | 2.952 | 1.917 | 4.545 |
| Stem cell transplant | <.0001 | 0.344 | 0.000 | 0.505 |
| Therapy administered | ||||
| Low-intensity therapies* | .005 | 0.529 | 0.000 | 0.827 |
| HMA/venetoclax* | .010 | 0.496 | 0.000 | 0.845 |
| Induction therapy* | .236 | 0.732 | 0.437 | 1.226 |
Compared with supportive care.